ArticleScientific reports2022

The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study.

Liangkun You et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.